Last reviewed · How we verify
Product 2 - AquaCelle Fish Oil Ethyl Ester
Product 2 - AquaCelle Fish Oil Ethyl Ester is a Omega-3 fatty acid supplement / Triglyceride-lowering agent Small molecule drug developed by RDC Clinical Pty Ltd. It is currently FDA-approved for Hypertriglyceridemia management, Cardiovascular health support.
AquaCelle Fish Oil Ethyl Ester provides omega-3 polyunsaturated fatty acids (EPA and DHA) that reduce triglycerides and support cardiovascular health.
AquaCelle Fish Oil Ethyl Ester provides omega-3 polyunsaturated fatty acids (EPA and DHA) that reduce triglycerides and support cardiovascular health. Used for Hypertriglyceridemia management, Cardiovascular health support.
At a glance
| Generic name | Product 2 - AquaCelle Fish Oil Ethyl Ester |
|---|---|
| Sponsor | RDC Clinical Pty Ltd |
| Drug class | Omega-3 fatty acid supplement / Triglyceride-lowering agent |
| Target | Multiple targets including PPAR-alpha, GPR120, and hepatic lipid metabolism pathways |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fish oil ethyl esters are concentrated forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) derived from fish sources. These omega-3 fatty acids work by reducing hepatic triglyceride synthesis, increasing fatty acid oxidation, and modulating inflammatory pathways, thereby lowering serum triglyceride levels and supporting cardiovascular function.
Approved indications
- Hypertriglyceridemia management
- Cardiovascular health support
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Fish aftertaste
- Bleeding tendency (at high doses)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Product 2 - AquaCelle Fish Oil Ethyl Ester CI brief — competitive landscape report
- Product 2 - AquaCelle Fish Oil Ethyl Ester updates RSS · CI watch RSS
- RDC Clinical Pty Ltd portfolio CI
Frequently asked questions about Product 2 - AquaCelle Fish Oil Ethyl Ester
What is Product 2 - AquaCelle Fish Oil Ethyl Ester?
How does Product 2 - AquaCelle Fish Oil Ethyl Ester work?
What is Product 2 - AquaCelle Fish Oil Ethyl Ester used for?
Who makes Product 2 - AquaCelle Fish Oil Ethyl Ester?
What drug class is Product 2 - AquaCelle Fish Oil Ethyl Ester in?
What development phase is Product 2 - AquaCelle Fish Oil Ethyl Ester in?
What are the side effects of Product 2 - AquaCelle Fish Oil Ethyl Ester?
What does Product 2 - AquaCelle Fish Oil Ethyl Ester target?
Related
- Drug class: All Omega-3 fatty acid supplement / Triglyceride-lowering agent drugs
- Target: All drugs targeting Multiple targets including PPAR-alpha, GPR120, and hepatic lipid metabolism pathways
- Manufacturer: RDC Clinical Pty Ltd — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertriglyceridemia management
- Indication: Drugs for Cardiovascular health support
- Compare: Product 2 - AquaCelle Fish Oil Ethyl Ester vs similar drugs
- Pricing: Product 2 - AquaCelle Fish Oil Ethyl Ester cost, discount & access